AnaptysBio Inc (NASDAQ:ANAB) — Market Cap & Net Worth
Market Cap & Net Worth: AnaptysBio Inc (ANAB)
AnaptysBio Inc (NASDAQ:ANAB) has a market capitalization of $1.54 Billion ($1.54 Billion) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7269 globally and #2146 in its home market, demonstrating a 9.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AnaptysBio Inc's stock price $56.77 by its total outstanding shares 29100902 (29.10 Million). Review how much debt does AnaptysBio Inc carry to assess the company's total debt and financial obligations.
AnaptysBio Inc Market Cap History: 2017 to 2026
AnaptysBio Inc's market capitalization history from 2017 to 2026. Data shows growth from $2.93 Billion to $1.65 Billion (13.70% CAGR).
Index Memberships
AnaptysBio Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.06% | #198 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #788 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.09% | #125 of 263 |
Weight: AnaptysBio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AnaptysBio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AnaptysBio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.01x
AnaptysBio Inc's market cap is 6.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.93 Billion | $10.00 Million | -$30.07 Million | 293.10x | N/A |
| 2018 | $1.86 Billion | $5.00 Million | -$61.66 Million | 371.27x | N/A |
| 2019 | $472.89 Million | $8.00 Million | -$97.34 Million | 59.11x | N/A |
| 2020 | $625.67 Million | $75.00 Million | -$19.93 Million | 8.34x | N/A |
| 2021 | $1.01 Billion | $63.17 Million | -$57.80 Million | 16.01x | N/A |
| 2022 | $901.84 Million | $10.29 Million | -$128.72 Million | 87.67x | N/A |
| 2023 | $623.34 Million | $17.16 Million | -$163.62 Million | 36.33x | N/A |
| 2024 | $385.30 Million | $91.28 Million | -$145.23 Million | 4.22x | N/A |
| 2025 | $1.41 Billion | $234.60 Million | -$13.23 Million | 6.01x | N/A |
Competitor Companies of ANAB by Market Capitalization
Companies near AnaptysBio Inc in the global market cap rankings as of June 18, 2026.
Key companies related to AnaptysBio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
AnaptysBio Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, AnaptysBio Inc's market cap moved from $2.93 Billion to $ 1.65 Billion, with a yearly change of 13.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.65 Billion | +17.10% |
| 2025 | $1.41 Billion | +266.16% |
| 2024 | $385.30 Million | -38.19% |
| 2023 | $623.34 Million | -30.88% |
| 2022 | $901.84 Million | -10.82% |
| 2021 | $1.01 Billion | +61.63% |
| 2020 | $625.67 Million | +32.31% |
| 2019 | $472.89 Million | -74.53% |
| 2018 | $1.86 Billion | -36.67% |
| 2017 | $2.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of AnaptysBio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.54 Billion USD |
| MoneyControl | $1.54 Billion USD |
| MarketWatch | $1.54 Billion USD |
| marketcap.company | $1.54 Billion USD |
| Reuters | $1.54 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more